Research programme: non-hallucinogenic psychiatric therapies - Daiichi Sankyo/Psylo
Latest Information Update: 24 Aug 2023
At a glance
- Originator Psylo
- Developer Daiichi Sankyo Company; Psylo
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Mental disorders